Afschin Gandjour

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Topics

Radical Prostatectomy

Top Venues

Applied health economics and health policy

PharmacoEconomics

The European journal of health economics : HEPAC : health economics in prevention and care

This page only lists publications with an associated author ORCID identifier.

Publications

Afschin Gandjour
Determining the societal value of a prospective drug for ME/CFS in Germany. PloS one 19 (7) (2024)
Afschin Gandjour
Determining the societal value of a prospective drug for ME/CFS in Germany. PloS one 19 (7) (2024)
Afschin Gandjour
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment. The European journal of health economics : HEPAC : health economics in prevention and care (2023)
Afschin Gandjour
Comment on: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" Applied health economics and health policy (2023)
Afschin Gandjour
A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany. Applied health economics and health policy (2023)
Afschin Gandjour
Optimal allocation of scarce PCR tests during the COVID-19 pandemic. PloS one 18 (6) (2023)
Afschin Gandjour
Cost-effectiveness of future lockdown policies against the COVID-19 pandemic. Health services management research (2022)
Afschin Gandjour
Comment on "Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective". PharmacoEconomics (2022)
Afschin Gandjour
Demonstrating the value of cancer biomarkers at the population level. The European journal of health economics : HEPAC : health economics in prevention and care 23 (4) (2022)
Afschin Gandjour
Optimal Sample Size Calculation for Clinical Research under a Budget Constraint. Medical decision making : an international journal of the Society for Medical Decision Making 42 (4) (2022)
Afschin Gandjour
Financial Incentives in the Path to Recovery from the COVID-19 Pandemic. Applied health economics and health policy (2021)
Afschin Gandjour
How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany. Applied health economics and health policy 19 (2) (2021)
Afschin Gandjour
Deterministic Sensitivity Analysis Under Ignorance. PharmacoEconomics 39 (10) (2021)
Valerie Ann Luyckx, Andrew D Rule, Katherine R Tuttle, Pierre Delanaye, Helen Liapis, Afschin Gandjour, Paola Romagnani, Hans-Johachim Anders
Nephron overload as a therapeutic target to maximize kidney lifespan. Nature reviews. Nephrology (2021)
Afschin Gandjour, Dennis A Ostwald
Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. Applied health economics and health policy 18 (1) (2020)
Afschin Gandjour
Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG. BMC health services research 20 (1) (2020)
Afschin Gandjour
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results. PloS one 15 (10) (2020)
Afschin Gandjour, Wencke Armsen, Wolfgang Wehmeyer, Jan Multmeier, Ulrich Tschulena
Costs of patients with chronic kidney disease in Germany. PloS one 15 (4) (2020)
Afschin Gandjour
A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency. BMC health services research 20 (1) (2020)
Afschin Gandjour
Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly. The European journal of health economics : HEPAC : health economics in prevention and care 21 (4) (2019)
Afschin Gandjour, Dennis A Ostwald
Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany. PharmacoEconomics 36 (10) (2019)
Afschin Gandjour
Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation". PharmacoEconomics 35 (5) (2019)
Mujaheed Shaikh, Afschin Gandjour
Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two-step instrumental variables strategy. Health economics 28 (1) (2018)